Active Ingredient
Incorporates North American (Kentucky/95) & Eurasian (Newmarket/2/93) EIV A1 & A2 strains

Indication
For the active immunisation against Equine Rhinopneumonitis-Influenza Virus infections.

Characteristics

• EHV-1 equine respiratory origin isolate
• Incorporates North American (Kentucky/95) & Eurasian (Newmarket/2/93) EIV A1 & A2 strains
• Killed vaccine with a novel adjuvant
• No reversion to virulence concern
• Flexible routes of administration (intra-muscular and intra-nasal)
• Includes pliable nasal applicator
• Three dose regimen conforms to AAEP recommendations.
• Safe for use in pregnant mares
• Also available as a monovalent vaccine (Calvenza® EHV, Calvenza® EIV)

Application
intra-muscular as well as intra-nasal application